MedTrace Logo

Zevalin-beam for Aggressive Lymphoma

NCT00491491 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-08-31

Study results available
· View outcomes & findings →

Summary

The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall and disease-free survival.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

ibritumomab tiuxetan

0.4 mCi/kg

PROCEDURE

BEAM chemotherapy and autologous stem-cell transplantation

Sponsors & Collaborators

  • City of Hope Medical Center

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • University of Göttingen

    collaborator OTHER

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Avichai Shimoni, MD · Chaim Sheba Medical Center, Tel Hashomer, Israel

  • Amrita Krishnan, MD · City of Hope National Medical Center, Duarte, CA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • United States
  • Germany
  • Israel
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00491491 on ClinicalTrials.gov